SVRN, Inc.
SVRN Appoints Patrick O'Kain as Chief Operating Officer
Former Borderless Capital General Partner, KPMG crypto practice co-lead, and U.S. Department of Justice special agent to lead SVRN's operations NEW…
Category
Business press releases
284 releases
Fastly, Inc.
Fastly Announces Third Quarter 2026 Financial Results
Record third quarter revenue of $190.2 million grew 20% year-over-year
Dover
Dover Completes Acquisition of Leistung
Dover Corporation (NYSE: DOV) today announced that it has completed the previously reported acquisition of Leistung Engineering Pvt. Ltd., which will…
Amcor
Amcor Reports Solid Results for Quarter ended September 30, 2026
Net sales of $6,129 million up 7% over prior-year Diluted EPS of $0.52; Adjusted Diluted EPS of $0.95 GAAP Net Income of $242 million Adjusted EBITDA…
Blue Owl Capital Corporation
Blue Owl Capital Corporation Announces September 30, 2026 Financial Results
Blue Owl Capital Corporation (NYSE: OBDC) ("OBDC" or the "Company") today announced financial results for its third quarter ended September 30, 2026.…
TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp. Announces
Third Quarter 2026 Financial Results
Silvaco Group, Inc.
Silvaco Reports Third Quarter 2026 Financial Results
Won major new tier-1 FTCO customer and 4 tier-1 customers for Jivaro Pro in Q3
Granite Point Mortgage Trust Inc.
Granite Point Mortgage Trust Inc. Reports
Third Quarter 2026 Financial Results
Cytek Biosciences, Inc.
Cytek Biosciences Reports Third Quarter 2026 Financial Results
Klaviyo, Inc.
Klaviyo Delivers Solid Q3 with Enterprise Growth, Multi-Product Strength, and Agent Traction
Third quarter revenue of $387.2 million, representing 25% year-over-year growth
Flyte Aviation, Inc.
Flyte Aviation Executes Letter of Intent to Sell Cardiology Assets
Proposed Sale to include VIVO and LockeT Cardiac Electrophysiology product lines Divestiture would Complete the Company's Planned Transition to…
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
Dianthus Therapeutics, Inc. /DE/
Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN)
Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W on track, with top-line results expected in…